All In Biotech

Drug Trial Radar · NCT03201770

Cohort Event Monitoring Study of Pyramax®

Phase IIIb/IV Cohort Event Monitoring Study To Evaluate, In Real Life Setting, The Safety And Tolerability In Malaria Patients Of The Fixed-Dose Artemisinin-Based Combination Therapy Pyramax®

Last checked: Nov 19, 2026Latest source record: Jun 26, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

8,572

Actual

Start

Jun 22, 2017

Primary completion

Apr 10, 2019

Study completion Apr 10, 2019

Sponsor

Sponsor type
Industry
Collaborators
Medicines for Malaria Venture
First posted
Jun 28, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 3 months
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is to be performed in public health facilities in Central and West Africa where Pyramax will be used as treatment of uncomplicated malaria episodes, including repeat episodes. The study is to assess the safety of Pyramax, particularly in patients with underlying liver function abnormalities, in patients who have co-morbid conditions, such as HIV, and also in very small children (\<1 year of age).

Conditions

  • Malaria,Falciparum

Interventions

  • pyronaridine artesunateDrug

    Antimalarial treatment

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluation and identification of hepatic safety events, including raised liver function testsTime frame: Assessment up to Day 28.

Locations

5 sites in 5 countries. Site status is shown where the registry gives one.

  • The Biotechnology Center Nkolbisson, Univ of Yaounde I, Messa

    Yaoundé, Cameroon

  • Institut Pierre Richet / Institut National de SanPublique (IPR/INSP)

    Bouaké, Côte d’Ivoire

  • Centre de Recherche du Centre Hospitalier du Mont Amba

    Kinshasa, Democratic Republic of the Congo

  • CERMEL, Albert Schweitzer Hospital

    Lambaréné, Gabon

  • Centre de Santé FCRM, Hospital of Talangai

    Brazzaville, Republic of the Congo

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.